Double blind, two dose, randomized, placebo-controlled, cross-over clinical trial of the positive allosteric modulator at the alpha7 nicotinic cholinergic receptor AVL-3288 in schizophrenia patients

[1]  J. Lieberman,et al.  The past and future of novel, non-dopamine-2 receptor therapeutics for schizophrenia: A critical and comprehensive review. , 2019, Journal of psychiatric research.

[2]  J. Calabrese,et al.  The first implementation of the NIMH FAST-FAIL approach to psychiatric drug development , 2018, Nature Reviews Drug Discovery.

[3]  N. Swerdlow,et al.  Auditory System Target Engagement During Plasticity-Based Interventions in Schizophrenia: A Focus on Modulation of N-Methyl-D-Aspartate-Type Glutamate Receptor Function. , 2018, Biological psychiatry. Cognitive neuroscience and neuroimaging.

[4]  J. Kantrowitz.  N-methyl-d-aspartate-type glutamate receptor modulators and related medications for the enhancement of auditory system plasticity in schizophrenia , 2018, Schizophrenia Research.

[5]  Amity E. Green,et al.  The effects of glycine on auditory mismatch negativity in schizophrenia , 2018, Schizophrenia Research.

[6]  D. Javitt,et al.  Improvement in mismatch negativity generation during d-serine treatment in schizophrenia: Correlation with symptoms , 2018, Schizophrenia Research.

[7]  D. Javitt,et al.  A tale of two sites: Differential impairment of frequency and duration mismatch negativity across a primarily inpatient versus a primarily outpatient site in schizophrenia , 2018, Schizophrenia Research.

[8]  A. Othman,et al.  Efficacy and Safety of the α7-Nicotinic Acetylcholine Receptor Agonist ABT-126 in the Treatment of Cognitive Impairment Associated With Schizophrenia: Results From a Phase 2b Randomized Controlled Study in Smokers. , 2017, The Journal of clinical psychiatry.

[9]  J. Kantrowitz,et al.  Managing Negative Symptoms of Schizophrenia: How Far Have We Come? , 2017, CNS Drugs.

[10]  M. Bloch,et al.  Alpha-7 nicotinic agonists for cognitive deficits in neuropsychiatric disorders: A translational meta-analysis of rodent and human studies , 2017, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[11]  R. Freedman,et al.  First in human trial of a type I positive allosteric modulator of alpha7-nicotinic acetylcholine receptors: Pharmacokinetics, safety, and evidence for neurocognitive effect of AVL-3288 , 2017, Journal of psychopharmacology.

[12]  M. Ahissar,et al.  Neurophysiological mechanisms of cortical plasticity impairments in schizophrenia and modulation by the NMDA receptor agonist D-serine. , 2016, Brain : a journal of neurology.

[13]  J. McCracken,et al.  Derisking Psychiatric Drug Development: The NIMH's Fast Fail Program, A Novel Precompetitive Model. , 2016, Journal of clinical psychopharmacology.

[14]  A. Othman,et al.  A Randomized Trial to Assess the Efficacy and Safety of ABT-126, a Selective α7 Nicotinic Acetylcholine Receptor Agonist, in the Treatment of Cognitive Impairment in Schizophrenia. , 2016, The American journal of psychiatry.

[15]  G. Dunbar,et al.  Phase 2 Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) in Negative and Cognitive Symptoms of Schizophrenia. , 2016, Schizophrenia bulletin.

[16]  Michael F. Green,et al.  Social cognition in schizophrenia , 2015, Nature Reviews Neuroscience.

[17]  Philip D. Harvey,et al.  Report on ISCTM Consensus Meeting on Clinical Assessment of Response to Treatment of Cognitive Impairment in Schizophrenia , 2015, Schizophrenia bulletin.

[18]  Joshua L. Phillips,et al.  Functional and Neuroanatomic Specificity of Episodic Memory Dysfunction in Schizophrenia: A Functional Magnetic Resonance Imaging Study of the Relational and Item-Specific Encoding Task. , 2015, JAMA psychiatry.

[19]  D. Hilt,et al.  Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an α7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia , 2015, Neuropsychopharmacology.

[20]  N. Andreasen.  Scale for the Assessment of Negative Symptoms , 2014 .

[21]  R. Maex,et al.  Understanding the Role α7 Nicotinic Receptors Play in Dopamine Efflux in Nucleus Accumbens , 2014, ACS chemical neuroscience.

[22]  H. Meltzer,et al.  The novel α7 nicotinic acetylcholine receptor agonist EVP-6124 enhances dopamine, acetylcholine, and glutamate efflux in rat cortex and nucleus accumbens , 2014, Psychopharmacology.

[23]  D. Umbricht,et al.  A Randomized, Placebo-Controlled Study Investigating the Nicotinic α7 Agonist, RG3487, for Cognitive Deficits in Schizophrenia , 2014, Neuropsychopharmacology.

[24]  R. Freedman.  α7-nicotinic acetylcholine receptor agonists for cognitive enhancement in schizophrenia. , 2014, Annual review of medicine.

[25]  S. Preskorn,et al.  Normalizing Effects of EVP-6124, an Alpha-7 Nicotinic Partial Agonist, on Event-Related Potentials and Cognition: A Proof of Concept, Randomized Trial in Patients with Schizophrenia , 2014, Journal of psychiatric practice.

[26]  J. Lieberman,et al.  A Randomized Exploratory Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) for Cognitive Enhancement in Schizophrenia , 2013, Neuropsychopharmacology.

[27]  Johannes Kornhuber,et al.  Allosteric alpha-7 nicotinic receptor modulation and P50 sensory gating in schizophrenia: A proof-of-mechanism study , 2013, Neuropharmacology.

[28]  Michael F. Green,et al.  From perception to functional outcome in schizophrenia: modeling the role of ability and motivation. , 2012, Archives of general psychiatry.

[29]  D. Javitt,et al.  Auditory emotion recognition impairments in schizophrenia: relationship to acoustic features and cognition. , 2012, The American journal of psychiatry.

[30]  Andrew P. Yonelinas,et al.  Neural correlates of relational and item-specific encoding during working and long-term memory in schizophrenia , 2012, NeuroImage.

[31]  Reto Meuli,et al.  Glutathione Precursor, N-Acetyl-Cysteine, Improves Mismatch Negativity in Schizophrenia Patients , 2008, Neuropsychopharmacology.

[32]  K. Gee,et al.  Nootropic α7 nicotinic receptor allosteric modulator derived from GABAA receptor modulators , 2007, Proceedings of the National Academy of Sciences.

[33]  R. Freedman,et al.  Genetics of Chromosome 15q13-q14 in Schizophrenia , 2006, Biological Psychiatry.

[34]  Robert Freedman,et al.  Proof-of-Concept Trial of an α7 Nicotinic Agonist in Schizophrenia , 2006 .

[35]  Ann Summerfelt,et al.  Review of clinical correlates of P50 sensory gating abnormalities in patients with schizophrenia. , 2005, Schizophrenia bulletin.

[36]  J. Lieberman,et al.  Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. , 2005, The New England journal of medicine.

[37]  Robert Freedman,et al.  Varied effects of atypical neuroleptics on P50 auditory gating in schizophrenia patients. , 2004, The American journal of psychiatry.

[38]  Gary Remington,et al.  Dopamine D2 receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient , 2001, Biological Psychiatry.

[39]  R. Buchanan,et al.  A separate disease within the syndrome of schizophrenia. , 2001, Archives of general psychiatry.

[40]  J. Gold,et al.  Repeatable battery for the assessment of neuropsychological status as a screening test in schizophrenia I: sensitivity, reliability, and validity. , 1999, The American journal of psychiatry.

[41]  C. Randolph,et al.  The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. , 1998, Journal of clinical and experimental neuropsychology.

[42]  Robert Freedman,et al.  Increased levels of the nicotine metabolite cotinine in schizophrenic smokers compared to other smokers , 1997, Biological Psychiatry.

[43]  H. Coon,et al.  Schizophrenia and Nicotinic Receptors , 1994, Harvard review of psychiatry.

[44]  N. Andreasen.  The Scale for the Assessment of Negative Symptoms (SANS): Conceptual and Theoretical Foundations , 1989, British Journal of Psychiatry.

[45]  R Freedman,et al.  Neurophysiological evidence for a defect in inhibitory pathways in schizophrenia: comparison of medicated and drug-free patients. , 1983, Biological psychiatry.

[46]  J. Overall,et al.  The Brief Psychiatric Rating Scale , 1962 .

[47]  J. Lieberman,et al.  Utility of Imaging-Based Biomarkers for Glutamate-Targeted Drug Development in Psychotic Disorders: A Randomized Clinical Trial , 2018, JAMA psychiatry.

[48]  Michael F. Green,et al.  Modeling Deficits From Early Auditory Information Processing to Psychosocial Functioning in Schizophrenia , 2017, JAMA psychiatry.

[49]  Robert Freedman,et al.  Sensory processing dysfunction in the personal experience and neuronal machinery of schizophrenia. , 2015, The American journal of psychiatry.

[50]  J. Ragland,et al.  Relational and Item-Specific Encoding (RISE): task development and psychometric characteristics. , 2012, Schizophrenia bulletin.

[51]  R. Freedman,et al.  Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. , 2006, Archives of general psychiatry.

[52]  R. Gur,et al.  Symptoms Versus Neurocognitive Test Performance as Predictors of Psychosocial Status in Schizophrenia: A 1- and 4-Year Prospective Study , 2005 .

[53]  J R Hughes,et al.  Prevalence of smoking among psychiatric outpatients. , 1986, The American journal of psychiatry.